Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone

Metabolism: Clinical and Experimental

Volumn 60, Issue 2, 2011, Pages 277-283

  Antonelli, Alessandro ^a   Ferrari, Silvia Martina ^a   Fallahi, Poupak ^a   Piaggi, Simona ^a   Paolicchi, Aldo ^a   Franceschini, Stefano Sellari ^a   Salvi, Mario ^b   Ferrannini, Ele ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; ENDOCRINE OPHTHALMOPATHY; FIBROBLAST; GRAVES DISEASE; HUMAN; HUMAN CELL; ORBIT; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN DNA BINDING;

ADIPOCYTES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLS, CULTURED; CHEMOKINE CXCL10; FEMALE; FIBROBLASTS; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; NF-KAPPA B; PPAR GAMMA; THIAZOLIDINEDIONES; THYROID GLAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78751645777     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.02.002     Document Type: Article

References (45)

1. Antonelli A., Rotondi M., and Ferrari S. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists J Clin Endocrinol Metab 91 2006 614 620
2. Starkey K., Heufelder A., and Bakerm G. Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use? J Clin Endocrinol Metab 88 2003 55 59
3. Valyasevi R.W., Harteneck D.A., and Dutton C.M. Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts J Clin Endocrinol Metab 87 2002 2352 2358
4. Kumar S., Coenen M.J., and Scherer Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy J Clin Endocrinol Metab 89 2004 930 935
5. Garcià-Lòpez M.A., Sancho D., and Sànchez-Madrid F. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+lymphocytes J Clin Endocrinol Metab 86 2001 5008 5016
6. Marazuela M., Postigo A.A., and Acevedo A. Adhesion molecules from the LFA-1/ICAM-1,3 and VLA-4/VCAM-1 pathways on T lymphocytes and vascular endothelium in Graves' and Hashimoto's thyroid glands Eur J Immunol 24 1994 2483 2490
7. Antonelli A., Saracino A., and Alberti B. High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy Acta Endocrinol (Copenh) 126 1992 13 23
8. Baschieri L., Antonelli A., and Nardi S. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy Thyroid 7 1997 579
9. Bahn R.S., Gorman C.A., and Johnson C.M. Presence of antibodies in the sera of patients with Graves' disease recognizing a 23 kilodalton fibroblast protein J Clin Endocrinol Metab 69 1989 622 628
10. Marx N., Mach F., and Sauty A. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells J Immunol 164 2000 6503 6508
11. Antonelli A., Ferrari S.M., and Fallahi P. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists Endocr Relat Cancer 16 2009 1299 1311
12. Mariotti S., Del Prete G.F., and Mastromauro C. The autoimmune infiltrate of Basedow's disease: analysis of clonal level and comparison with Hashimoto's thyroiditis Exp Clin Endocrinol 97 1991 139 146
13. De Carli M., D'Elios M.M., and Mariotti S. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy J Clin Endocrinol Metab 77 1993 1120 1124
14. Aniszewski J.P., Valyasevi R.W., and Bahn R.S. Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy J Clin Endocrinol Metab 85 2000 776 780
15. Watson P.F., Pickerill A.P., and Davies R. Analysis of cytokine gene expression in Graves' disease and multinodular goiter J Clin Endocrinol Metab 79 1994 355 360
16. Hiromatsu Y., Yang D., and Bednarczuk T. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy J Clin Endocrinol Metab 85 2000 1194 1199
17. Wakelkamp I.M., Bakker O., and Baldeschi L. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients Clin. Endocrinol (Oxf) 58 2003 280 287
18. Antonelli A., Ferrari S.M., and Fallahi P. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists J Clin Endocrinol Metab 94 2009 1803 1809
19. Antonelli A., Ferri C., and Fallahi P. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis-a longitudinal study Rheumatology (Oxford) 47 2008 45 49
20. Wakelkamp I.M., Gerding M.N., and Van Der Meer J.W. Both Th1- and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy Clin Exp Immunol 121 2000 453 457
21. Forster G., Otto E., and Hansen C. Analysis of orbital T cells in thyroid-associated ophthalmopathy Clin Exp Immunol 112 1998 427 434
22. Schaefer K.L., Denevich S., and Ma C. Intestinal antiinflammatory effects of thiazolidinedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms Inflamm Bowel Dis 11 2005 244 252
23. Schulthess F.T., Paroni F., and Sauter N.S. CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling Cell Metab 9 2009 125 139
24. Gosset P., Charbonnier A.S., and Delerive P. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells Eur J Immunol 31 2001 2857 2865
25. Desreumaux P., Dubuquoy L., and Nutten S. Attenuation of colon inflammation through activators of the retinoid × receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies J Exp Med 193 2001 827 838
26. Lewis J.D., Lichtenstein G.R., and Stein R.B. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis Am J Gastroenterol 96 2001 3323 3328
27. Diab A., Deng C., and Smith J.D. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis J Immunol 168 2002 2508 2515
28. Setoguchi K., Misaki Y., and Terauchi Y. Peroxisome proliferator- activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis J Clin Invest 108 2001 1667 1675
29. Ellis C.N., Varani J., and Fisher G.J. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation Arch Dermatol 136 2000 609 616
30. Clark R.B., Bishop-Bailey D., and Estrada-Hernandez T. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses J Immunol 164 2000 1364 1371
31. Ray D.M., Akbiyik F., and Phipps R.P. The peroxisome proliferator- activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms J Immunol 177 2006 5068 5076
32. Ricote M., Li A.C., and Willson T.M. The peroxisome proliferator- activated receptor-gamma is a negative regulator of macrophage activation Nature 391 1998 79 82
33. Ricote M., Welch J.S., and Glass C.K. Regulation of macrophage gene expression by the peroxisome proliferator-activated receptor-gamma Horm Res 54 2000 275 280
34. Chen F., Wang M., and O'Connor J.P. Phosphorylation of PPARgamma via active ERK1/2 leads to its physical association with p65 and inhibition of NF-kappabeta J Cell Biochem 90 2003 732 744
35. Welch J.S., Ricote M., and Akiyama T.E. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages Proc Natl Acad Sci U S A 100 2003 6712 6717
36. Chawla A., Barak Y., and Nagy L. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation Nat Med 7 2001 48 52
37. Pascual G., Fong A.L., and Ogawa S. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma Nature 437 2005 759 763
38. Kim H.J., Rho Y.H., and Choi S.J. 15-Deoxy-delta12,14-PGJ2 inhibits IL-6-induced Stat3 phosphorylation in lymphocytes Exp Mol Med 37 2005 179 185
39. Soller M., Tautenhahn A., and Brüne B. Peroxisome proliferator-activated receptor gamma contributes to T lymphocyte apoptosis during sepsis J Leukoc Biol 79 2006 235 243
40. Mimura L.Y., Villares S.M., and Monteiro M.L. Peroxisome proliferator-activated receptor-gamma gene expression in orbital adipose/connective tissues is increased during the active stage of Graves' ophthalmopathy Thyroid 13 2003 845 850
41. Feldon S.E., O'loughlin C.W., and Ray D.M. Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes Am J Pathol 169 2006 1183 1193
42. Levin F., Kazim M., and Smith T.J. Rosiglitazone-induced proptosis Arch Ophthalmol 123 2005 119 121
43. Ray D.M., Spinelli S.L., and O'Brien J.J. Platelets as a novel target for PPARgamma ligands: implications for inflammation, diabetes, and cardiovascular disease BioDrugs 20 2006 231 241
44. Zhang F., Lavan B.E., and Gregoire F.M. Selective modulators of PPAR-gamma activity: molecular aspects related to obesity and side-effects PPAR Res 2007 2007 32696
45. Misra P., Chakrabarti R., and Vikramadithyan R.K. PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic J Pharmacol Exp Ther 306 2003 763 771